(0.27%) 5 145.50 points
(0.28%) 38 548 points
(0.38%) 17 914 points
(-0.82%) $83.16
(1.30%) $1.948
(-0.10%) $2 344.80
(1.20%) $27.58
(0.62%) $927.80
(-0.26%) $0.932
(-0.22%) $11.00
(-0.38%) $0.797
(0.88%) $92.68
Live Chart Being Loaded With Signals
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments...
Stats | |
---|---|
Šios dienos apimtis | 2.19M |
Vidutinė apimtis | 2.59M |
Rinkos kapitalizacija | 46.61B |
EPS | HKD0.562 ( 2023-09-30 ) |
Last Dividend | HKD0.616 ( 2023-05-25 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 13.81 |
ATR14 | HKD0.0890 (0.25%) |
Tūris Koreliacija
Hangzhou Tigermed Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Hangzhou Tigermed Koreliacija - Valiuta/Žaliavos
Hangzhou Tigermed Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD7.38B |
Bruto pelnas: | HKD2.85B (38.58 %) |
EPS: | HKD2.34 |
FY | 2023 |
Pajamos: | HKD7.38B |
Bruto pelnas: | HKD2.85B (38.58 %) |
EPS: | HKD2.34 |
FY | 2022 |
Pajamos: | HKD7.09B |
Bruto pelnas: | HKD2.81B (39.64 %) |
EPS: | HKD2.32 |
FY | 2021 |
Pajamos: | HKD5.21B |
Bruto pelnas: | HKD2.27B (43.55 %) |
EPS: | HKD3.31 |
Financial Reports:
No articles found.
Hangzhou Tigermed Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.616 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.362 | 2021-05-25 |
Last Dividend | HKD0.616 | 2023-05-25 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD1.557 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.54 | -- |
Div. Sustainability Score | 8.20 | |
Div.Growth Potential Score | 5.20 | |
Div. Directional Score | 6.70 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8476.HK | Ex Dividend Knight | 2023-08-22 | Annually | 0 | 0.00% | |
2039.HK | Ex Dividend Junior | 2023-07-25 | Annually | 0 | 0.00% | |
1109.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
0175.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
3788.HK | Ex Dividend Knight | 2023-10-05 | Annually | 0 | 0.00% | |
1681.HK | Ex Dividend Knight | 2023-06-08 | Semi-Annually | 0 | 0.00% | |
0716.HK | Ex Dividend Junior | 2023-09-11 | Annually | 0 | 0.00% | |
2233.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
1257.HK | No Dividend Player | 2023-09-12 | Annually | 0 | 0.00% | |
0316.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.274 | 1.500 | 4.52 | 6.77 | [0 - 0.5] |
returnOnAssetsTTM | 0.0682 | 1.200 | 7.73 | 9.27 | [0 - 0.3] |
returnOnEquityTTM | 0.0978 | 1.500 | -0.0245 | -0.0367 | [0.1 - 1] |
payoutRatioTTM | 0.291 | -1.000 | 7.09 | -7.09 | [0 - 1] |
currentRatioTTM | 2.74 | 0.800 | 1.295 | 1.036 | [1 - 3] |
quickRatioTTM | 2.71 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.793 | 1.500 | 1.151 | 1.727 | [0.2 - 2] |
debtRatioTTM | 0.114 | -1.500 | 8.10 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8 465.38 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.951 | 2.00 | 9.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.589 | 2.00 | 9.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.161 | -1.500 | 9.35 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.386 | 1.000 | 6.90 | 6.90 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.337 | 1.000 | 5.26 | 5.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.499 | 1.000 | 8.34 | 8.34 | [0.2 - 2] |
assetTurnoverTTM | 0.249 | 0.800 | -1.675 | -1.340 | [0.5 - 2] |
Total Score | 8.20 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.30 | 1.000 | 8.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0978 | 2.50 | -0.0157 | -0.0367 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.589 | 2.00 | 9.47 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.980 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.951 | 2.00 | 9.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.291 | 1.500 | 7.09 | -7.09 | [0 - 1] |
pegRatioTTM | 0.152 | 1.500 | -2.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.229 | 1.000 | 6.78 | 0 | [0.1 - 0.5] |
Total Score | 5.20 |
Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.